Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Gliclazide Action Pathway
Homo sapiens
Drug Action Pathway
Gliclazide is a sulfonylurea drug used in the treatment of type 2 diabetes. Gliclazide acts on pancreatic beta-cells to stimulate insulin secretion. Under physiological conditions, insulin secretion from beta-cells is mediated by elevated glucose concentration in the blood. Glucose enters the cell via GLUT2 (SLC2A2) transporters. Once inside the cell, glucose is metabolized to produce ATP. High concentration of ATP will inhibit ATP-dependent potassium channels (ABCC8), which depolarizes the cell. Depolarization causes opening of voltage-gated calcium channels, allowing calcium to enter cell. High intracellular calcium subsequently stimulate vesicle exocytosis and insulin secretion. Gliclazide stimulates insulin secretion by directly inhibiting ATP-dependent potassium channels.
References
Gliclazide Pathway References
Mizuno CS, Chittiboyina AG, Kurtz TW, Pershadsingh HA, Avery MA: Type 2 diabetes and oral antihyperglycemic drugs. Curr Med Chem. 2008;15(1):61-74.
Pubmed: 18220763
Pancreas Function References
Roder PV, Wu B, Liu Y, Han W: Pancreatic regulation of glucose homeostasis. Exp Mol Med. 2016 Mar 11;48:e219. doi: 10.1038/emm.2016.6.
Pubmed: 26964835
Gaisano HY, Macdonald PE, Vranic M: Glucagon secretion and signaling in the development of diabetes. Front Physiol. 2012 Sep 4;3:349. doi: 10.3389/fphys.2012.00349. eCollection 2012.
Pubmed: 22969729
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings